Marc Antoine Valantin

Summary

Country: France

Publications

  1. ncbi Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients
    M A Valantin
    Department of Infectious Diseases, AP HP, Pitie Salpetriere Hospital, Paris, France
    J Antimicrob Chemother 65:556-61. 2010
  2. ncbi The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006-2010
    Marc Arthur Loko
    INSERM, U897 and ISPED, Universite Victor Segalen, Bordeaux, France
    BMC Infect Dis 10:303. 2010
  3. ncbi Resistant minority species are rarely observed in patients on darunavir/ritonavir monotherapy
    Sidonie Lambert-Niclot
    AP HP, Pitie Salpetriere Hospital, INSERM U 943 and Pierre et Marie Curie University, Paris, France
    J Antimicrob Chemother 67:1470-4. 2012
  4. ncbi Raltegravir as functional monotherapy leads to virological failure and drug resistance in highly treatment-experienced HIV-infected patients
    Fabienne Caby
    Service des Maladies Infectieuses et Tropicales, Assistance Publique Hopitaux de Paris, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Scand J Infect Dis 42:527-32. 2010
  5. ncbi Similar evolution of cellular HIV-1 DNA level in darunavir/ritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeks
    Sidonie Lambert-Niclot
    AP HP, Pitie Salpetriere Hospital, INSERM U 943 and Pierre et Marie Curie University Paris, Paris, France
    PLoS ONE 7:e41390. 2012
  6. ncbi Role of HIV-1 minority populations on resistance mutational pattern evolution and susceptibility to protease inhibitors
    Benedicte Roquebert
    Department of Virology, Pitie Salpetriere Hospital, Paris, France
    AIDS 20:287-9. 2006
  7. ncbi MIV-310 reduces HIV viral load in patients failing multiple antiretroviral therapy: results from a 4-week phase II study
    Christine Katlama
    Département des Maladies Infectieuses et Tropicales INSERM E0214, Hopital Pitie Salpetriere, Paris, France
    AIDS 18:1299-304. 2004
  8. ncbi Resistance mutations before and after tenofovir regimen failure in HIV-1 infected patients
    Marc Wirden
    Department of Virology, Pitie Salpetriere Hospital, Paris, France
    J Med Virol 76:297-301. 2005
  9. ncbi Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia
    Marc Wirden
    Department of Virology, Pitie Salpetriere Hospital, 83 bvd de l Hôpital, 75013 Paris, France
    J Antimicrob Chemother 66:709-12. 2011
  10. ncbi Factors associated with virological failure in HIV-1-infected patients receiving darunavir/ritonavir monotherapy
    Sidonie Lambert-Niclot
    Department of Virology and Infectious Diseases, AP HP, Pitie Salpetriere Hospital, INSERM U 943 and Pierre et Marie Curie University, Paris, France
    J Infect Dis 204:1211-6. 2011

Detail Information

Publications28

  1. ncbi Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients
    M A Valantin
    Department of Infectious Diseases, AP HP, Pitie Salpetriere Hospital, Paris, France
    J Antimicrob Chemother 65:556-61. 2010
    ..To assess the impact of switching to tenofovir disoproxil fumarate + emtricitabine on lipid parameters...
  2. ncbi The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006-2010
    Marc Arthur Loko
    INSERM, U897 and ISPED, Universite Victor Segalen, Bordeaux, France
    BMC Infect Dis 10:303. 2010
    ..The ANRS CO 13 HEPAVIH cohort was set up to explore these critical questions.To describe the cohort aims and organization, monitoring and data collection procedures, baseline characteristics, as well as follow-up findings to date...
  3. ncbi Resistant minority species are rarely observed in patients on darunavir/ritonavir monotherapy
    Sidonie Lambert-Niclot
    AP HP, Pitie Salpetriere Hospital, INSERM U 943 and Pierre et Marie Curie University, Paris, France
    J Antimicrob Chemother 67:1470-4. 2012
    ....
  4. ncbi Raltegravir as functional monotherapy leads to virological failure and drug resistance in highly treatment-experienced HIV-infected patients
    Fabienne Caby
    Service des Maladies Infectieuses et Tropicales, Assistance Publique Hopitaux de Paris, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Scand J Infect Dis 42:527-32. 2010
    ..If persistent low viraemia is observed over more than 48 weeks without the emergence of resistance, RAL should never be given as functional monotherapy, as it is associated with a maximal risk of VF and the emergence of RAL resistance...
  5. ncbi Similar evolution of cellular HIV-1 DNA level in darunavir/ritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeks
    Sidonie Lambert-Niclot
    AP HP, Pitie Salpetriere Hospital, INSERM U 943 and Pierre et Marie Curie University Paris, Paris, France
    PLoS ONE 7:e41390. 2012
    ..Our objectives were to study the impact of 96 weeks of Darunavir/ritonavir monotherapy versus a triple standard combination on the HIV-1 blood reservoir and factors associated with HIV-1 plasma DNA at baseline in MONOI trial sub-study...
  6. ncbi Role of HIV-1 minority populations on resistance mutational pattern evolution and susceptibility to protease inhibitors
    Benedicte Roquebert
    Department of Virology, Pitie Salpetriere Hospital, Paris, France
    AIDS 20:287-9. 2006
    ..These minor species, not detected by standard genotype, may influence PI susceptibility...
  7. ncbi MIV-310 reduces HIV viral load in patients failing multiple antiretroviral therapy: results from a 4-week phase II study
    Christine Katlama
    Département des Maladies Infectieuses et Tropicales INSERM E0214, Hopital Pitie Salpetriere, Paris, France
    AIDS 18:1299-304. 2004
    ..MIV-310 (alovudine), a nucleoside reverse transcriptase inhibitor, potently inhibits the replication of highly mutated strains of HIV in vitro. We examined the efficacy of MIV-310 in highly pretreated patients...
  8. ncbi Resistance mutations before and after tenofovir regimen failure in HIV-1 infected patients
    Marc Wirden
    Department of Virology, Pitie Salpetriere Hospital, Paris, France
    J Med Virol 76:297-301. 2005
    ..The K65R mutation can emerge even with TAMs or L74V. No obvious impact was shown on the TAMs or other NRTI mutations, although a trend towards emergence of some particular mutations was observed...
  9. ncbi Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia
    Marc Wirden
    Department of Virology, Pitie Salpetriere Hospital, 83 bvd de l Hôpital, 75013 Paris, France
    J Antimicrob Chemother 66:709-12. 2011
    ..Analyses of proviral HIV-DNA can provide information about the viral reservoir, because integrated DNA reflects both actively and latently infected cells...
  10. ncbi Factors associated with virological failure in HIV-1-infected patients receiving darunavir/ritonavir monotherapy
    Sidonie Lambert-Niclot
    Department of Virology and Infectious Diseases, AP HP, Pitie Salpetriere Hospital, INSERM U 943 and Pierre et Marie Curie University, Paris, France
    J Infect Dis 204:1211-6. 2011
    ..Our objective was to determine virological and clinical characteristics associated with virological failure in human immunodeficiency virus (HIV)-infected patients switching to darunavir/ritonavir (DRV/r) monotherapy...
  11. ncbi Impact of hepatitis C and liver fibrosis on antiretroviral plasma drug concentrations in HIV-HCV co-infected patients: the HEPADOSE study
    Stephanie Dominguez
    AP HP, Département de Maladies Infectieuses et Tropicales, INSERM U720, CHU Pitie Salpetriere, Paris, France
    J Antimicrob Chemother 65:2445-9. 2010
    ..To compare plasma antiretroviral concentrations in HIV-HCV co-infected and in matched HIV mono-infected patients...
  12. ncbi Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial
    Jade Ghosn
    Department of Internal Medicine and Infectious Diseases, AP HP, Bicetre University Hospital, Le Kremlin Bicetre Cedex, France
    HIV Med 11:137-42. 2010
    ..MONotherapy AntiRetroviral Kaletra (MONARK) is the first randomized trial comparing lopinavir/ritonavir monotherapy to triple combination therapy with zidovudine/lamivudine and lopinavir/ritonavir in antiretroviral-naïve patients...
  13. ncbi Influence of interferon-based therapy on liver fibrosis progression in HIV/HCV coinfected patients: a retrospective repeated liver biopsy analysis
    Patrick Ingiliz
    Hepatology Department, Pitie Salpetriere Hospital, Paris, France
    J Hepatol 56:49-54. 2012
    ..The course of the disease is determined by the rapidity of liver fibrosis progression (LFP). The influence of interferon on LFP in coinfected patients has yet not been evaluated by comparative liver biopsies...
  14. ncbi Impact of stavudine phenotype and thymidine analogues mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial
    Vincent Calvez
    Department of Virology and Infectious Diseases and Pitie Salpetrière Hospital, Paris, France
    Antivir Ther 7:211-8. 2002
    ....
  15. ncbi Acute hepatitis C in HIV-infected patients: rare spontaneous clearance correlates with weak memory CD4 T-cell responses to hepatitis C virus
    Aurelie Schnuriger
    INSERM, UMRS 945, Paris, France
    AIDS 23:2079-89. 2009
    ..To explore the parameters of specific immunity to hepatitis C virus (HCV) associated with virus clearance during acute HCV infection in HIV coinfection...
  16. ncbi Six-year follow-up of hepatitis B surface antigen concentrations in tenofovir disoproxil fumarate treated HIV-HBV-coinfected patients
    Vincent Thibault
    Virology Laboratory, Hopital Pitie Salpetriere, Assistance Publique, Paris, France
    Antivir Ther 16:199-205. 2011
    ..Our main objective was to study the kinetics of HBsAg level in HIV-HBV-coinfected patients with undetectable HBV DNA load under treatment containing tenofovir disoproxil fumarate (TDF)...
  17. ncbi Efficacy and safety of adefovir dipivoxil plus pegylated interferon-alpha2a for the treatment of lamivudine-resistant hepatitis B virus infection in HIV-infected patients
    Patrick Ingiliz
    Hepatology Department, Pitie Salpetriere Hospital, Paris, France
    Antivir Ther 13:895-900. 2008
    ..Adefovir dipivoxil (ADV) has shown its efficacy for treating 3TC-resistant (3TC-R) HBV in HIV-coinfected patients. ADV combined with pegylated interferon (PEG-IFN) has never been evaluated in this population...
  18. ncbi Dual raltegravir/etravirine combination in virologically suppressed HIV-1-infected patients on antiretroviral therapy
    Ruxandra Călin
    Infectious Diseases Department, Hopital Pitie Salpetriere, Paris, France
    Antivir Ther 17:1601-4. 2012
    ..The objective of this study was to evaluate the capacity of dual RAL/ETR therapy to maintain virological suppression in HIV-1 patients under effective antiretroviral therapy (ART)...
  19. ncbi HIV-1 genome is often defective in PBMCs and rectal tissues after long-term HAART as a result of APOBEC3 editing and correlates with the size of reservoirs
    Slim Fourati
    Université Pierre et Marie Curie Paris, 4 place Jussieu, Paris, France
    J Antimicrob Chemother 67:2323-6. 2012
    ..Precise characterization of viruses present in reservoirs in long-term pretreated patients will be a major issue to consider in the context of viral eradication. We assessed the frequency of defective viruses present in cellular reservoirs...
  20. ncbi Low frequency of intermittent HIV-1 semen excretion in patients treated with darunavir-ritonavir at 600/100 milligrams twice a day plus two nucleoside reverse transcriptase inhibitors or monotherapy
    Sidonie Lambert-Niclot
    Department of Virology, Pitie Salpetriere Hospital, 83 Boulevard de l hopital, Paris, France
    Antimicrob Agents Chemother 54:4910-3. 2010
    ..The median darunavir seminal plasma concentration was close to the blood plasma free fraction, demonstrating a good penetration of darunavir into the male genital tract...
  21. ncbi Fat tissue distribution changes in HIV-infected patients treated with lopinavir/ritonavir. Results of the MONARK trial
    Sami Kolta
    Paris Descartes University, Medicine Faculty, UPRES EA 4058, Assistance Publique Hopitaux de Paris, Cochin Hospital, Paris, France
    Curr HIV Res 9:31-9. 2011
    ..06; 95% CI, 1.11-78.69). These results suggest that LPV/r, and possibly other protease inhibitors, may not be the main contributor to lipoatrophy in HIV-infected patients receiving triple therapy...
  22. ncbi Impact of reduced dosing of lopinavir/ritonavir in virologically controlled HIV-infected patients: the Kaledose trial
    Jean Luc Meynard
    Hopital Saint Antoine, AP HP, Paris, France
    J Antimicrob Chemother 65:125-8. 2010
    ..It is debated whether a risk of protease inhibitor mutation selection in proviral DNA exists during intermittent HIV-1 viraemia thereby impacting long-term virological control...
  23. ncbi Determinants of low-density lipoprotein particle diameter during antiretroviral therapy including protease inhibitors in HIV-1-infected patients
    Randa Bittar
    Unité Fonctionnelle de Biochimie des Maladies Métaboliques, Service de Biochimie Métabolique, Groupe Hospitalier Pitie Salpetriere, Assistance Publique Hopitaux de Paris, Paris, France
    Antivir Ther 17:855-60. 2012
    ..This cross-sectional substudy of the ANRS 126 trial was designed to identify variables influencing LDL diameter...
  24. ncbi Lateral rectus muscle paralysis induced by ribavirin and pegylated interferon-α2a in a patient with HIV/HCV co-infection
    Guillaume Mellon
    Infectious Diseases Department, La Pitie Salpetriere Hospital, 83 Boulevard de l hopital, 75013 Paris, France
    J Infect Chemother 18:937-8. 2012
    ..Symptoms fully resolved with treatment interruption without any ophthalmological sequelae. This side effect is rare and has never been reported in a HIV-HCV co-infected patient...
  25. ncbi Effect of alendronate on HIV-associated osteoporosis: a randomized, double-blind, placebo-controlled, 96-week trial (ANRS 120)
    Sylvie Rozenberg
    AP HP, Groupe Hospitalier Pitie Salpetriere, Service de Rhumatologie, Paris, France
    AIDS Res Hum Retroviruses 28:972-80. 2012
    ..1% (95% CI 2.8 to 9.3); p=0.0003]. Alendronate 70 mg weekly for 96 weeks improves BMD in HIV-1-infected patients on antiretroviral therapy...
  26. ncbi Muscle and liver lactate metabolism in HAART-treated and naive HIV-infected patients: the MITOVIR study
    Jade Ghosn
    Department des Maladies Infectieuses, CHU Pitie Salpetriere, AP HP, Universite Pierre et Marie Curie, Paris, France
    Antivir Ther 10:543-50. 2005
    ..To assess the impact of nucleoside analogue reverse transcriptase inhibitor (NRTI) combination therapy on muscle and liver lactate metabolism in HIV-infected patients...
  27. ncbi Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro
    Isabelle Malet
    Laboratoire de Virologie, Hopital Pitie Salpetriere, Assistance Publique Hopitaux de Paris, EA 2387, Universite Pierre et Marie Curie Paris 6, Paris, France
    Antimicrob Agents Chemother 52:1351-8. 2008
    ..These mutations led to strong impairment of enzymes in vitro in the absence of raltegravir: strand transfer activity was affected, and in some cases 3' processing was also impaired...
  28. ncbi Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy
    Patrick Ingiliz
    Hepatology Department, AP HP, GH Pitié Salpétrière, Paris, France
    Hepatology 49:436-42. 2009
    ..Conclusions: HIV-infected patients on combined antiretroviral therapy with chronic transaminase elevation of unknown origin have a high rate of liver lesions, mostly consistent with NASH related to insulin resistance...